iiinova — where your digital self keeps evolving

JAMA Dermatology @jamadermatology.com · 13h

For pediatric patients aged ≥4 to <12 years with #HairLoss, international expert consensus supports #LowDoseOralMinoxidil for selected hair follicle, hair cycle, and hair shaft disorders, with structured dosing and reassessment guidance. ja.ma/4jyh1AF

ja.ma

Low-Dose Oral Minoxidil Use for Pediatric Hair Disorders

This international Consensus Statement seeks to establish international expert consensus on recommendations for use of low-dose oral minoxidil to treat pediatric patients with hair disorders.

000

JAMA Dermatology @jamadermatology.com · 13h

Among children with #EpidermalDifferentiationDisorders, growth impairment was genotype specific and most evident early in life, with persistent height deficits in SPINK5 and attenuation of early deficits in ABCA12 and KRT10. ja.ma/4hmMpko

Figure 2. Bar Graph of Growth Impairment. Three side-by-side graphs show percentile (0-100) for A) Weight, B) Height, and C) Head circumference by Age (0-24, 25-48, >48 months). Each age group compares five conditions: AR-nEDD, SPINK5-sEDD, Keratinopathic-nEDD, FLG-nEDD, STS-sEDD, with error bars.

000

JAMA Dermatology @jamadermatology.com · 25/09/2026

Elephantiasic #PretibialMyxedema can present with marked lower-extremity swelling, nodular hyperplasia, and toe clubbing in patients with Graves disease. ja.ma/3TeDLuZ

Figure 1. Clinical Image. Bilateral lower-extremity prominent swelling with multiple variably sized pink nodules and associated clubbing of the toes seen at presentation.

000

JAMA Dermatology @jamadermatology.com · 24/09/2026

For #PseudofolliculitisBarbae, expert consensus supports behavioral modification of hair removal practices as first-line therapy, with topical, systemic, and laser-based treatment options also recommended. ja.ma/4d2516E

Table shows characteristics of 13 Delphi Panelists. All are board-certified dermatologists (2 military, 11 nonmilitary). Practice settings: 5 academic, 8 private. Geographic regions include 5 Northeast, 4 South, 2 Midwest, and 2 West.

000

JAMA Dermatology @jamadermatology.com · 24/09/2026

💬 Editorial: Permanent hair removal may be medically necessary gender-affirming care for transgender women and nonbinary individuals assigned male at birth when #Hirsutism contributes to gender dysphoria, misgendering, and reduced quality of life. ja.ma/4yekVn5

JAMA Dermatology editorial titled 'Permanent Hair Removal as Medically Necessary Gender-Affirming Care—Beyond the Cosmetic Label' by Gabriela Olmedo, Alexandr Trifonov, and Gwendolyn P. Quinn. Published online September 23, 2026.

000

JAMA Dermatology @jamadermatology.com · 23/09/2026

Among adults with cutaneous #LichenPlanus, ruxolitinib cream reduced lesions and itch vs vehicle cream and no serious treatment-emergent adverse events were observed. ja.ma/3TlD4Qn

JAMA Dermatology RCT summary: Ruxolitinib cream demonstrates 50% IGA-TS at week 16 compared to 21.9% for vehicle cream in 64 patients with cutaneous lichen planus. A bar chart shows Ruxolitinib consistently outperforming vehicle over 16 weeks.

000

JAMA Dermatology @jamadermatology.com · 23/09/2026

In a qualitative study of transgender women and nonbinary adults assigned male at birth, #Hirsutism was associated with stigma, social and romantic isolation, and gender dysphoria, and many participants described extensive efforts to conceal visible hair. ja.ma/47gzSZI

Table 3 lists main themes & representative quotes on hirsutism experiences, covering transphobia, urgency to remove hair, romantic rejection fears, extensive hair removal work, internalized stigma, & sources of support.

000

JAMA Dermatology @jamadermatology.com · 09/09/2026

In patients with #HidradenitisSuppurativa, #Interleukin17 inhibitors were not associated with a significant increase in inflammatory bowel disease risk vs placebo, and events were rare. ja.ma/46dYTo8

JAMA Dermatology article: "Inflammatory Bowel Disease and Interleukin-17 Inhibitors in Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis" by Cutrona, Jolkovsky, Romanelli et al. Published Online: September 9, 2026.

000

JAMA Dermatology @jamadermatology.com · 09/09/2026

#Omalizumab for #ChronicUrticaria showed a median drug survival of 3.1 years, with treatment most often discontinued after disease control, supporting its sustained real-world benefit. ja.ma/4gTW3tc

Figure 1. Kaplan-Meier Curves of Overall Omalizumab Drug Survival Over Time. The probability of drug survival, in %, decreases from 100% at 0 years to approximately 35% at 7 years. The number at risk starts at 3522 at 0 years and ends at 22 at 7 years.

000

JAMA Dermatology @jamadermatology.com · 20/08/2026

This case report describes a patient with a history of myasthenia gravis and thyoma who developed upper extremity myalgias and arthralgias after tapering prednisone. ja.ma/4x9ijGt

Figure 1. Clinical Photographs of Plaques. Image A shows a right leg, and image B shows a left leg. Both display oval, violaceous to brown plaques on the skin, highlighted by pink arrowheads.

001

JAMA Dermatology @jamadermatology.com · 20/08/2026

Coverage for #AtopicDermatitis specialty therapies varied widely across commercial payers, and most policies required step therapy beyond US Food and Drug Administration labeling. ja.ma/469Tyhk

Table 1 shows commercial coverage criteria for 7 Atopic Dermatitis specialty therapies in Aug 2025 across 89 policies. It details step therapy, prescriber requirements (e.g., consultation with a dermatologist), and diagnostic thresholds like BSA involvement, EASI, IGA, and SCORAD scores.

000

JAMA Dermatology @jamadermatology.com · 19/08/2026

In patients at high risk for #BasalCellCarcinoma, #ArtificialIntelligence-assisted line-field confocal optical coherence tomography identified subclinical facial lesions with a high positive predictive value. ja.ma/45SYXJP

A JAMA Dermatology article page. Title: AI-Assisted Line-Field Confocal Optical Coherence Tomography to Detect Subclinical Basal Cell Carcinoma. Authors include Moritz Ronicke, Laura Dürr. Published Online: August 19, 2026.

000

JAMA Dermatology @jamadermatology.com · 19/08/2026

#CherryAngiomas were more common and appeared at younger ages in individuals with #Neurofibromatosis type 1, supporting these lesions as a vascular manifestation of #NF1. ja.ma/4x9gLwf

Table 1: Clinical characteristics and histologic features of cherry angiomas (CAs). It compares individuals with and without NF1, detailing demographics (age, sex), presence of CAs, NF1 phenotypes, and skin biopsy results.

001

JAMA Dermatology @jamadermatology.com · 09/08/2026

For approved #HidradenitisSuppurativa #Biologics, adalimumab showed the most favorable cost-efficiency profile across the US, Canada, France, Germany, and Australia in this economic evaluation. ja.ma/4g49MgH

Six scatter plots show Adjusted HiSCR-50 response (%) vs. Annual treatment cost (in 1000s of US$) for Adalimumab, Bimekizumab, and Secukinumab under various pricing models (WAC, NADAC, Public Net, 50-70% Rebate). Adalimumab & Bimekizumab consistently show higher responses than Secukinumab.

000

JAMA Dermatology @jamadermatology.com · 08/08/2026

📣 This consensus statement reflects an expert-established classification framework for pyoderma gangrenosum phenotypes. ja.ma/4xsHxiz

Table 3: Pyoderma Gangrenosum (PG) Disease Modifiers. It lists extracutaneous manifestations (<1%) affecting organs (e.g., lungs, eyes), causing delayed diagnosis & increased mortality. Special sites (5-18%) on head/neck/genitals/peristomal skin influence prognosis & management.

000

JAMA Dermatology @jamadermatology.com · 08/08/2026

Six scatter plots compare Adalimumab, Bimekizumab, and Secukinumab therapies by adjusted HiSCR-50 response (%) vs. annual treatment cost (1000s of US$). Secukinumab consistently shows lower response and lower cost. Adalimumab and Bimekizumab offer higher response at varying higher costs depending on the rebate scenario.

000

JAMA Dermatology @jamadermatology.com · 03/08/2026

Many asymptomatic patients seeking routine skin examinations for #SkinCancer are at low risk, with most cancers found in older adults and those with lighter skin phototypes. ja.ma/3Tzg9B5

100

JAMA Dermatology @jamadermatology.com · 01/08/2026

Global burden of melanoma, cutaneous squamous cell carcinoma, and basal cell carcinoma increased from 1990 to 2023, with projections indicating further growth to 2050, especially in low- and middle-SDI regions. ja.ma/4h4jDFm

Bar graphs show prediction analysis of future skin cancer burden based on the Bayesian Age-Period-Cohort Model, comparing observed, predicted, and global data for malignant melanoma, squamous cell carcinoma, and basal cell carcinoma.

000

JAMA Dermatology @jamadermatology.com · 30/07/2026

📄 This case report describes a patient with adenopathy and extensive skin patch overlying a plasmacytoma (AESOP) syndrome with solitary plasmacytoma. ja.ma/4vR8Y4x

Figure 1: Patient features. A: Left anterior chest with inflamed lesion & markings. B: Hematoxylin-eosin stain of tissue (pink/purple cells). C: CD34 stain (brown vascular structures). D: Lesion after radiotherapy, showing reduced inflammation with red capillaries.

000

JAMA Dermatology @jamadermatology.com · 30/07/2026

📄 This case report describes a man in his 40s with a large nodular plaque on the upper back without associated pain, bleeding, or systemic symptoms. ja.ma/3RkVWhL

Histopathology of Lobomycosis, showing thick-walled yeastlike organisms in chains with tubular connections amidst granulomatous dermal inflammation. Image stained with hematoxylin-eosin at x100 magnification.

000

JAMA Dermatology @jamadermatology.com · 29/07/2026

In two independent birth cohorts, frequent early respiratory infections increased the risk of childhood #AtopicDermatitis, independent of genetic predisposition or antibiotic use. ja.ma/4vSYVvO

Two line graphs show atopic dermatitis prevalence (0-40%) by age (0-10 years) for Upper, Middle, and Lower tertiles. Graph 1 (Infection Episodes): AOR 1.61, P=.03. Graph 2 (Infection Days): AOR 1.69, P=.01. Upper tertile consistently shows the highest prevalence, peaking around age 2-3 in both.

111

JAMA Dermatology @jamadermatology.com · 29/07/2026

In advanced #UrothelialCarcinoma, enfortumab vedotin–induced cutaneous adverse events were independently associated with improved progression-free and overall survival, especially when skin reactions occurred within 15 days of treatment. ja.ma/4bjouip

Bar graph of Temporal Distribution of Cutaneous Adverse Events (cAE) Morphologic Features. Y-axis: 8 types of cAE morphology (e.g., Desquamative, Pruritus). X-axis: Time to onset (days) from 0-100. Horizontal bars show time ranges, with a black line for the median.

000

JAMA Dermatology @jamadermatology.com · 12/07/2026

Commercial payer-negotiated prices for 15 common #Dermatology procedures varied widely across US hospitals; median prices were lower than list, higher than #Medicare, and lower in rural vs nonrural facilities. ja.ma/4fskiz4

JAMA Dermatology article, "Commercial Price Variation for Common Dermatologic Procedures." Authors: Chelsea Deitelzweig, Ravi Dhawan, Kyle King, et al. Published Online: June 17, 2026. Includes links for author affiliations and article information.

000

JAMA Dermatology @jamadermatology.com · 11/07/2026

📄 This case report describes 2 household members who presented with intensely pruritic eruptions from the scalp to the extremities. ja.ma/3SVyoAi

Clinical image showing pale skin of an axilla, featuring dark hair and numerous scattered small, reddish, raised pruritic papules, consistent with poultry red mite bites.

000

JAMA Dermatology @jamadermatology.com · 11/07/2026

#GLP1RA use in adults with #HidradenitisSuppurativa was associated with lower mortality, major cardiovascular events, cellulitis, and sepsis over 1- and 2-year follow-up in a large matched cohort study. ja.ma/4yhddc8

A JAMA Dermatology research letter titled 'GLP-1 Receptor Agonist Use and Clinical Outcomes in Patients With Hidradenitis Suppurativa' by B. Jastrząb-Miśkiewicz, J.C. Szepietowski, and P.K. Krajewski. Published online July 1, 2026.

000

JAMA Dermatology @jamadermatology.com · 10/07/2026

This consensus statement develops a core outcome set of essential domains to be reported in #clinical trials evaluating the efficacy of interventions for facial #aging. ja.ma/4vhRTjX

Table 3: Core Outcome Set Items. This table presents outcomes, their definitions, and final vote percentages for inclusion. Top items (97% include) are Treatment duration, adverse events, & patient satisfaction. Lowest (86% include) is Overall assessment of focused area.

000

JAMA Dermatology @jamadermatology.com · 10/07/2026

In a large cohort of adults with hypopigmented #mycosis #fungoides, most had early-stage disease and responded well to skin-directed therapy, with stage progression observed in only 6%. ja.ma/4vxnQFi

Immunohistochemistry for CD4, original magnification × 100: Dense, diffuse reddish-brown stained cells are visible in the lower tissue area. Immunohistochemistry for CD8, original magnification × 100: Reddish-brown cells form a concentrated band at the top, with scattered cells below.

000

JAMA Dermatology @jamadermatology.com · 10/07/2026

In refractory #rosacea, paroxetine therapy was associated with systemic proteomic changes in neuro-vascular-immune pathways and identified circulating protein #biomarkers linked to #clinical improvement. ja.ma/4vnxvxQ

Volcano Plot & Bar Chart: Differentially Expressed Proteins in Rosacea. Plot A shows gene fold change vs. p-value; orange dots up, blue down. Plot B lists downregulated GO terms (Metabolism, Hormone, Immune, Neural) with tRNA metabolic process being most significant.

020

JAMA Dermatology @jamadermatology.com · 06/07/2026

010

JAMA Dermatology @jamadermatology.com · 04/07/2026

This consensus statement develops a core outcome set of essential domains to be reported in #clinical trials evaluating the efficacy of interventions for facial #aging. ja.ma/3QxIMO0

010

JAMA Dermatology @jamadermatology.com · 03/07/2026

In a large cohort of adults with hypopigmented #mycosis #fungoides, most had early-stage disease and responded well to skin-directed therapy, with stage progression observed in only 6%. ja.ma/4avmm6O

000

JAMA Dermatology @jamadermatology.com · 02/07/2026

JAMA Dermatology Research Letter: "GLP-1 Receptor Agonist Use and Clinical Outcomes in Patients With Hidradenitis Suppurativa." Authors: Beata Jastrząb-Miśkiewicz, Jacek C. Szepietowski, Piotr K. Krajewski. Published Online: July 1, 2026.

010

JAMA Dermatology @jamadermatology.com · 02/07/2026

#Rosacea network meta-analysis indicates that topical ivermectin and encapsulated benzoyl peroxide improved lesion count and IGA success more than metronidazole, though encapsulated benzoyl peroxide led to more treatment discontinuations. ja.ma/4eSn2Er

Screenshot of a JAMA Dermatology article: 'Topical Preparations for Moderate to Severe Rosacea Treatment: A Systematic Review and Network Meta-Analysis.' Authored by Amstutz et al., published online July 1, 2026, with DOI: 10.1001/jamadermatol.2026.2062.

001

JAMA Dermatology @jamadermatology.com · 26/06/2026

In a large cohort of adults with hypopigmented #mycosis #fungoides, most had early-stage disease and responded well to skin-directed therapy, with stage progression observed in only 6%. ja.ma/4eCAuMA

000

JAMA Dermatology @jamadermatology.com · 26/06/2026

This consensus statement develops a core outcome set of essential domains to be reported in #clinical trials evaluating the efficacy of interventions for facial #aging. ja.ma/3SrC1Oc

000

JAMA Dermatology @jamadermatology.com · 26/06/2026

000

JAMA Dermatology @jamadermatology.com · 26/06/2026

💬 Editorial: Efforts to unify remission criteria in #AtopicDermatitis through clinician and patient measures highlight progress for research and guidelines, yet require further evaluation for feasibility and patient relevance. ja.ma/4gCLOea

JAMA Dermatology article page. Editorial title: "The Challenge of Defining Atopic Dermatitis Remission" by Hywel Charles Williams, DSc. Published Online: April 15, 2026, in JAMA Dermatol, 2026;162;(6):555-556. Includes DOI & navigation links.

000

JAMA Dermatology @jamadermatology.com · 25/06/2026

This systematic review examines potential clinical, laboratory, and treatment-related factors associated with progression from acute to chronic urticaria. ja.ma/4g4T9TM

JAMA Dermatology article titled 'Progression From Acute to Chronic Urticaria: A Systematic Review'. Authored by Enrique Gómez de la Fuente, Francisco Javier Ortiz de Frutos, Noelia Álvarez-Díaz, et al. Published online June 24, 2026.

001

JAMA Dermatology @jamadermatology.com · 25/06/2026

Among more than 780 000 children in Denmark and England, #AtopicDermatitis was not linked to poorer academic performance on national exams regardless of disease phenotype or socioeconomic background. ja.ma/4oJrqdo

Diagram of longitudinal study designs for Denmark and England cohorts. Timelines from birth show various assessment windows for inclusion, exposure (AD diagnosis), covariates (demographics, comorbidities), and exclusion. Data observability is indicated by color, leading to follow-up periods ending at age 18 (Denmark) and 11.5 (England).

000

JAMA Dermatology @jamadermatology.com · 23/06/2026

In high-risk cutaneous squamous cell #carcinoma, ultrasonography and CT detected baseline nodal metastases more accurately than physical examination, but both modalities performed poorly in #immunosuppressed patients. ja.ma/4y1UOA7

JAMA Dermatology journal article titled "Diagnostic Modalities and Nodal Staging in High-Risk Cutaneous Squamous Cell Carcinoma." Authored by Carla Ferrándiz-Pulido, Álvaro Gómez-Tomás, Sahyly Siurana et al. Published online April 22, 2026.

000

JAMA Dermatology @jamadermatology.com · 21/06/2026

000

JAMA Dermatology @jamadermatology.com · 20/06/2026

📄 This case report describes 2 household members who presented with intensely pruritic eruptions from the scalp to the extremities. ja.ma/3Shrzsy

000

JAMA Dermatology @jamadermatology.com · 19/06/2026

In a large cohort of adults with hypopigmented #mycosis #fungoides, most had early-stage disease and responded well to skin-directed therapy, with stage progression observed in only 6%. ja.ma/3SQbWbz

001

JAMA Dermatology @jamadermatology.com · 19/06/2026

This consensus statement develops a core outcome set of essential domains to be reported in #clinical trials evaluating the efficacy of interventions for facial #aging. ja.ma/4xCtKH5

000

JAMA Dermatology @jamadermatology.com · 19/06/2026

000

JAMA Dermatology @jamadermatology.com · 17/06/2026

Keratinocyte carcinoma prevention with nicotinamide was cost-effective and patient-centered, reducing treatment costs and providing measurable quality-of-life benefit. ja.ma/4w0Jfaz

Figure. Histogram of Probabilistic Sensitivity Analysis. The Y-axis shows 'KC events, No.', X-axis 'Differential cost per QALY gained, $'. Distribution is skewed left, peaking near -70,000 to -80,000 at ~680 events, with a dotted line marking the central tendency. Range: -300,000 to 0.

010

JAMA Dermatology @jamadermatology.com · 16/06/2026

No significant difference in melanoma mortality trends was observed between Germany's #SkinCancerScreening program and neighboring countries, suggesting limited population-level impact. ja.ma/3QBvakB

Figure 1: Two line graphs show age-standardized melanoma mortality rates per 100,000 from 2009-2022. Graph A displays German regions (e.g., Bavaria), generally showing rates between 1-2. Graph B shows non-German regions (e.g., Denmark) with varying rates, some higher.

000

JAMA Dermatology @jamadermatology.com · 15/06/2026

Keratinocyte carcinoma prevention with nicotinamide was cost-effective and patient-centered, reducing treatment costs and providing measurable quality-of-life benefit. ja.ma/4e9TYJH

Figure. Histogram of Probabilistic Sensitivity Analysis. X-axis: Differential cost per QALY gained, $ (-300,000 to 0). Y-axis: KC events, No. (0-800). The data is left-skewed, peaking around -75,000, with a dotted line near the peak.

010